Sage Therapeutics, Inc. (SAGE) earnings
SAGE earnings moved a median of -0.29% by the close. Quarterly and annual SAGE reports and results, each read against the price at its own news timestamp. Back to the SAGE overview →
19 measured SAGE earnings events.
Where these SAGE earnings landedvs 17 measured SAGE earnings reactions
| Middle 50% of SAGE earnings reactions | -2.80% to +1.62% |
|---|---|
| Median reaction (to close) | -0.29% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 SAGE earnings events with a measured close landed between -2.80% and +1.62%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Sage Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Sage Therapeutics Announces Second Quarter 2025 Financial Results | Press release | — | — | |
| Form 10-Q Sage Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.93% | -2.80% | |
| Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates | Press release | +0.93% | -2.80% | |
| Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 | Press release | +0.14% | +1.62% | |
| Form 10-K Sage Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.56% | +0.56% | |
| Form 10-Q Sage Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.73% | -16.25% | |
| Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates | Press release | +2.73% | -16.25% | |
| Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 | Press release | +0.00% | -0.15% | |
| Form 10-Q Sage Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -4.32% | -8.44% | |
| Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress | Press release | -4.32% | -8.44% | |
| Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 | Press release | -0.33% | +0.83% | |
| Form 10-Q Sage Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.08% | -0.29% | |
| Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress | Press release | +3.08% | -0.29% | |
| Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 | Press release | +0.36% | -0.54% | |
| Form 10-K Sage Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.89% | +1.98% | |
| Form 10-Q Sage Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +6.52% | +8.87% | |
| Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress | Press release | +6.52% | +8.87% | |
| Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 | Press release | +1.07% | +2.03% |
Keep exploring
More SAGE: analyst actions → · SEC filings → · SAGE overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Natera, Inc. (NTRA) | 957 | +0.21% | 57% |
| Antares Pharma, Inc. (ATRS) | 951 | 0.00% | 43% |
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Intellia Therapeutics, Inc. (NTLA) | 948 | -0.24% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.